SCHEMBL16259348

SCHEMBL16259348

CN(C)CCOCCC(=O)OCCN(C)C

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DNM1 Q05193 1/20 0.59
CHRM2 P08172 1/20 0.52
CHRM4 P08173 1/20 0.52
CHRM5 P08912 1/20 0.52
CHRM1 P11229 1/20 0.52
CHRNB2 P17787 1/20 0.52
CHRM3 P20309 1/20 0.52
CHRNA4 P43681 1/20 0.52
CA12 O43570 2/20 0.44
CA1 P00915 2/20 0.44
CA2 P00918 2/20 0.44
CA9 Q16790 2/20 0.44
ALDH1A1 P00352 3/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
CYP1A2 P05177 1/20 0.42
CYP3A4 P08684 1/20 0.42
CYP2C19 P33261 1/20 0.42
GAA P10253 1/20 0.42
BLM P54132 2/20 0.41
PMP22 Q01453 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31750724 0.93 DNM1 (0.53) DNM1CHRM2CHRM4CHRM5CHRM1
SCHEMBL28365017 0.88 DNM1 (0.61) DNM1CHRM2CHRM4CHRM5CHRM1
SCHEMBL30997589 0.88 DNM1 (0.51) DNM1CHRM2CHRM4CHRM5CHRM1
SCHEMBL3038090 0.87 DNM1 (0.68) DNM1CHRM2CHRM4CHRM5CHRM1
SCHEMBL25868606 0.86 DNM1 (0.53) DNM1CHRM2CHRM4CHRM5CHRM1
SCHEMBL11668491 0.85 DNM1 (0.66) DNM1CHRM2CHRM4CHRM5CHRM1
SCHEMBL30997592 0.83 KMT2A (0.52) DNM1CHRM2CHRM4CHRM5CHRM1
SCHEMBL18232019 0.83 DNM1 (0.59) DNM1CHRM2CHRM4CHRM5CHRM1
SCHEMBL30997594 0.83 KMT2A (0.52) DNM1CHRM2CHRM4CHRM5CHRM1
SCHEMBL12540745 0.83 DNM1 (0.75) DNM1CHRM2CHRM4CHRM5CHRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025264781-A1 CATIONIZING AGENTS FOR SACCHARIDES AND METHODS KEMIRA OY J (FI) 2025-12-26 WO claimed
EP-4652152-A1 SURFACTANT COMPOSITIONS DERIVED FROM WASTE STREAMS, AND METHODS Kemira OYJ (FI) 2025-11-26 EP claimed
WO-2024155904-A1 SURFACTANT COMPOSITIONS DERIVED FROM WASTE STREAMS, AND METHODS KEMIRA OYJ (FI) 2024-07-25 WO claimed
WO-2025264781-A1 CATIONIZING AGENTS FOR SACCHARIDES AND METHODS KEMIRA OY J (FI) 2025-12-26 WO disclosed
EP-4652152-A1 SURFACTANT COMPOSITIONS DERIVED FROM WASTE STREAMS, AND METHODS Kemira OYJ (FI) 2025-11-26 EP disclosed
WO-2024155904-A1 SURFACTANT COMPOSITIONS DERIVED FROM WASTE STREAMS, AND METHODS KEMIRA OYJ (FI) 2024-07-25 WO disclosed
CN-110709149-A Method for purifying (meth) acrylic esters 阿科玛法国公司 2020-01-17 CN disclosed
US-10457630-B2 Reclamation of noble products in a method for producing (meth)acrylic ester ARKEMA FRANCE (FR) 2019-10-29 US disclosed
US-9359287-B2 Process for recovering noble products in a process for producing dialkylaminoalkyl (meth) acrylates ARKEMA FRANCE (FR) 2016-06-07 US disclosed
US-20140350291-A1 PROCESS FOR RECOVERING NOBLE PRODUCTS IN A PROCESS FOR PRODUCING DIALKYLAMINOALKYL (METH) ACRYLATES ARKEMA FRANCE (FR) 2014-11-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10457630-B2 Reclamation of noble products in a method for producing (meth)acrylic ester MMAB, ALKBH5, ALKBH3 DNM1 3758/4885CHRM2 1857/4885CHRM4 1388/4885
US-20140350291-A1 PROCESS FOR RECOVERING NOBLE PRODUCTS IN A PROCESS FOR PRODUCING DIALKYLAMINOALKYL (METH) ACRYLATES MMAB, ACR, ALKBH5 DNM1 2604/4885CHRM2 3966/4885CHRM4 3310/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.